James Raftery: NICE: “inconsistent,” “in large part arbitrary and opaque,” according to friends

A strong critique just published points to logical inconsistencies in NICE’s consideration of social values, specifically in how it handles quality adjusted life years (QALYs). Since these are key to many of the most controversial decisions made by NICE’s appraisal committees, this matters. It matters all the more that the authors include Tony Culyer, who […]

Read More…

James Raftery: Sofosbuvir for hepatitis C—moving to country specific prices

The National Institute for Health and Care Excellence (NICE) has provisionally approved sofosbuvir (brand name Sovaldi) for the treatment of hepatitis C, a decision that has surprised some commentators given its high price. The drug’s price in the United States of $84k for a 12 week course would be £54.6k at the current exchange rate of $/£0.65. But Gilead […]

Read More…

David Kerr: Self obsessing health technology

Has the health tech industry and those who fund it lost the plot? Apparently, the next must have technology is the connected toothbrush. A “data driven oral health startup” company in the United States has just received a multi-million dollar investment to further develop a smartphone connected toothbrush. With this toothbrush, an accelerometer measures how […]

Read More…

Liz Wager: Research integrity—how can institutions balance discipline and support?

The suicide of Yoshiki Sasai is both tragic and shocking. Sasai was deputy director of the RIKEN Center for Developmental Biology, and a co-author of reports in Nature on the phenomenon of “stimulus-triggered acquisition of pluripotency” (or STAP), which were retracted. Although Sasai was not accused of misconduct himself, he was criticised in an institutional […]

Read More…